GERM

Amplify Treatments, Testing and Advancements ETF

Fund Details

Data as of: N/A
TickerGERM™
Inception
06/17/2020
Primary ExchangeNYSE Arca
CUSIP032108581
Net AssetsN/A
Shares OutstandingN/A
# of Holdings (view all holdings)N/A
Expense Ratio:0.68%

Index Details

Index Name Prime Treatments, Testing and Advancements Index
Index Ticker PGERMN
Index Provider Prime Indexes
Weighting Methodology Modified Equal Weight
Rebalance Frequency Quarterly
Index Website primeindexes.com
Index Methodology

Why Invest in GERM?

  • Healthcare advancements have had the most impact in combating different diseases, with vaccines, therapies and testing being at the forefront of those developments.
  • Global biotechnology market was valued at $1.55 trillion in 2023 and is projected to grow at a CAGR of 13.96% from 2024 to 2030.1
  • There are over 20 combined epidemic and pandemic-prone diseases affecting the world today.2
  • More than 50 variants of the coronavirus have been identified.3

Objective and Strategy

GERM seeks investment results that generally correlate (before fees and expenses) to the total return performance of the Prime Treatments, Testing and Advancements Index. GERM holds U.S.-listed companies engaged in and at the forefront of R&D, vaccines, therapies and testing technologies.

NAV and Market Price

Data as of: N/A
Previous Day's NAV Previous Day's Market Price
Net Asset Value N/A Closing Price N/A
Daily Change N/A Daily Change N/A
% Daily Change N/A % Daily Change N/A
30-Day Median Bid/Ask Spread N/A Premium/Discount % N/A
Premium Discount History

Daily Price/NAV Performance

Data as of: N/A
 

Fund Holdings

Data as of: N/A
TOP 10 HOLDINGS

Fund holdings are subject to change at any time and should not be considered recommendations to buy or sell any security.

Country Allocation

Data as of: N/A

Market Capitalization

Data as of: N/A
LARGE CAP (> $10B): N/A
MID CAP ($2B - $10B): N/A
SMALL CAP ($300M - < $2B): N/A

Fund holdings are subject to change at any time and should not be considered recommendations to buy or sell any security.

Performance

  CUMULATIVE (%) ANNUALIZED (%)  
  1 Mo. 3 Mo. 6 Mo. YTD Since Inception
(06/17/20)
1 Yr. 3 Yr. 5 Yr. Since Inception
(06/17/20)
Month end as of TBD
Fund NAV N/A N/A N/A N/A N/A N/A N/A N/A N/A
Closing Price N/A N/A N/A N/A N/A N/A N/A N/A N/A
Prime Treatments, Testing and Advancements Index N/A N/A N/A N/A N/A N/A N/A N/A N/A
Quarter end as of TBD
Fund NAV N/A N/A N/A N/A N/A N/A N/A N/A N/A
Closing Price N/A N/A N/A N/A N/A N/A N/A N/A N/A
Prime Treatments, Testing and Advancements Index N/A N/A N/A N/A N/A N/A N/A N/A N/A

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. Short-term performance, in particular, is not a good indication of the fund’s future performance, and an investment should not be made based solely on returns. Brokerage commissions will reduce returns. A fund’s NAV is the sum of all its assets less any liabilities, divided by the number of shares outstanding. The closing price or market price is the most recent price at which the fund was traded.

Indexes are unmanaged and it’s not possible to invest directly in an index. The Prime Treatments, Testing, and Advancements Index tracks the performance of companies engaged in R&D, vaccines, therapies, and testing technologies.

Premium/Discount

Data as of: N/A
 

The table and line graph are provided to show the frequency at which the closing price of the Fund was at a premium (above) or discount (below) to the Fund's daily net asset value ("NAV"). The table and line graph represent past performance and cannot be used to predict future results. Shareholders may pay more than NAV when buying Fund shares and receive less than an NAV when those shares are sold because shares are bought and sold at current market prices.

Calendar Year Calendar Year through
Days traded at premium N/A N/A
Days traded at net asset value N/A N/A
Days traded at discount N/A N/A

GERM Distributions

EX-DATERECORD DATEPAYABLE DATEAMOUNT

2020

2021

2022

2023

2024

03/26/24 03/27/24 03/28/24 $0.05578
06/27/24 06/27/24 06/28/24 $0.08798
09/27/24 09/27/24 09/30/24
12/30/24 12/30/24 12/31/24

There is no guarantee that distributions will be made.

1Biotechnology Market Size, Share & Growth Report, 2030 (grandviewresearch.com)
CAGR is the compound annual growth rate.

2World Health Organization: http://www.emro.who.int/pandemic-epidemic-diseases/health-topics/related-health-topics.html

3COVID Variants and Strains (webmd.com)

Investing involves risk, including loss of principal. Shares of any ETF are bought and sold at market price (not NAV), may trade at a discount or premium to NAV and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Narrowly focused investments typically exhibit higher volatility. Treatment Companies and Testing Companies are involved in discovering, developing and commercializing novel drugs or tests with significant market potential. These companies face challenges including pre-clinical testing and clinical trial stages of development. Clinical trials may be delayed and certain programs may never advance in the clinic or may be more costly to conduct than anticipated. Such companies may be dependent on their ability to secure significant funding for research, development, and commercialization of therapeutics, vaccines, tests, and other health care products or services. If there are delays in obtaining required regulatory and marketing approvals for products, the ability of such companies to generate revenue may be materially impaired. If regulatory approval is obtained, products will still remain subject to regulatory scrutiny with regulatory authorities having the ability to impose significant restrictions on the indicated uses or marketing. Lastly, even if a licensed product is achieved, such companies may encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management, or shipping.

Prior to 1/29/24, the Amplify Treatments, Testing and Advancements ETF was formerly the ETFMG Treatments, Testing and Advancements ETF.

Amplify Investments LLC is the Investment Adviser to the Fund, and Toroso Investments, LLC serves as the Investment Sub-Adviser.

Amplify ETFs are distributed by Foreside Fund Services, LLC.

Subscribe

Receive the latest news and insights from Amplify.